Q1 2017 13F Holders as of 31 Mar 2017
-
Type / Class
-
Equity / Ordinary Shares, nominal value EUR0.05 per share
-
Shares outstanding
-
95,490,450
-
Total 13F shares
-
5,703,192
-
Share change
-
+43,979
-
Total reported value
-
$136,879,000
-
Put/Call ratio
-
463%
-
Price per share
-
$24.00
-
Number of holders
-
39
-
Value change
-
+$1,857,397
-
Number of buys
-
16
-
Number of sells
-
15
Institutional Holders of Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share (CLLS) as of Q1 2017
As of 31 Mar 2017,
Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share (CLLS) was held by
39 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,703,192 shares.
The largest 10 holders included
FMR LLC, ORBIMED ADVISORS LLC, Tekla Capital Management LLC, LAZARD ASSET MANAGEMENT LLC, FRANKLIN RESOURCES INC, SPHERA FUNDS MANAGEMENT LTD., Artal Group S.A., Abingworth LLP, venBio Select Advisor LLC, and DAFNA Capital Management LLC.
This page lists
39
institutional shareholders reporting positions in this security
for the Q1 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.